Laser vision correction specialist LCA-Vision (LCAV) is poised for an epic rebound. After suffering through a multi-year recession, it has quietly re-emerged as more disciplined and efficient organization, with the most attractive long-term growth prospects in company history. Significant pent-up demand and a game-changing demographic inflection point remain under-appreciated by the market. Given the substantial operating leverage in LCA-Vision's fixed cost business model, disciplined investors could reap a 200% TSR in the next 36 months. Downside risk is mitigated by adroit financial management and a robust balance sheet with $1.80 per share net cash.
Reasons to Consider LCAV
The trifecta of headwinds that punished shareholders over these past five years have quietly transitioned to tail winds.
Only subscribers can access this article, which is part of the PRO research library covering 3,603 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: